249 related articles for article (PubMed ID: 30770225)
1. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
[TBL] [Abstract][Full Text] [Related]
2. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
Pan XJ; Feng YM; Zhuang GH
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
[TBL] [Abstract][Full Text] [Related]
3. Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.
Carlos F; Gómez JA; Anaya P; Romano-Mazzotti L
Hum Vaccin Immunother; 2016; 12(1):52-63. PubMed ID: 26503702
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China.
Zhuang GH; Pan XJ; Wang XL
Vaccine; 2008 Aug; 26(35):4608-16. PubMed ID: 18597903
[TBL] [Abstract][Full Text] [Related]
5. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
[TBL] [Abstract][Full Text] [Related]
8. Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach.
Hayajneh WA; Daniels VJ; James CK; Kanıbir MN; Pilsbury M; Marks M; Goveia MG; Elbasha EH; Dasbach E; Acosta CJ
BMC Infect Dis; 2018 Mar; 18(1):119. PubMed ID: 29514609
[TBL] [Abstract][Full Text] [Related]
9. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands).
Postma MJ; Bos JM; Beutels P; Schilthuis H; van den Hoek JA
Vaccine; 2004 May; 22(15-16):1862-7. PubMed ID: 15121296
[TBL] [Abstract][Full Text] [Related]
10. Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.
Shedrawy J; Henriksson M; Hergens MP; Askling HH
Vaccine; 2018 Nov; 36(50):7659-7665. PubMed ID: 30385058
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of hepatitis A vaccination for adults in Belgium.
Luyten J; Van de Sande S; de Schrijver K; Van Damme P; Beutels P
Vaccine; 2012 Sep; 30(42):6070-80. PubMed ID: 22858555
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children.
Hankin-Wei A; Rein DB; Hernandez-Romieu A; Kennedy MJ; Bulkow L; Rosenberg E; Trigg M; Nelson NP
Vaccine; 2016 Jul; 34(35):4243-4249. PubMed ID: 27317459
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility of universal hepatitis A vaccination in Canada.
Bauch CT; Anonychuk AM; Pham BZ; Gilca V; Duval B; Krahn MD
Vaccine; 2007 Dec; 25(51):8536-48. PubMed ID: 17996339
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of hepatitis A prevention in travellers.
Tormans G; Van Damme P; Van Doorslaer E
Vaccine; 1992; 10 Suppl 1():S88-92. PubMed ID: 1335668
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of hepatitis A vaccination in Indonesia.
Suwantika AA; Beutels P; Postma MJ
Hum Vaccin Immunother; 2014; 10(8):2342-9. PubMed ID: 25424941
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C.
Chapko MK; Yee HS; Monto A; Dominitz JA
Vaccine; 2010 Feb; 28(7):1726-31. PubMed ID: 20044051
[TBL] [Abstract][Full Text] [Related]
17. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
[TBL] [Abstract][Full Text] [Related]
18. Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.
Cheng X; Zhao Y; Zhang X; Jin H; Min J
Hum Vaccin Immunother; 2017 Aug; 13(8):1873-1878. PubMed ID: 28448739
[TBL] [Abstract][Full Text] [Related]
19. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.
Anonychuk AM; Tricco AC; Bauch CT; Pham B; Gilca V; Duval B; John-Baptiste A; Woo G; Krahn M
Pharmacoeconomics; 2008; 26(1):17-32. PubMed ID: 18088156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
